Monday, November 16, 2026
Alpha Dart Therapy clears tumors in five brain cancer patients
A treatment called Alpha Dart Therapy produced complete tumor clearance in five patients with brain cancer. The report describes the therapy's effect in these patients.
Alpha Tau says Alpha DaRT worked in all eight brain cancer patients treated
Alpha Tau reported that its Alpha DaRT therapy was deliverable in every one of the eight people with recurring glioblastoma who received it. Of the six who could be assessed, five saw their tumors fully respond and one partly responded, and no unexpected severe side effects occurred.
Sunday, November 15, 2026
Alpha Tau Medical reports positive interim data from U.S. REGAIN trial in recurrent glioblastoma
Alpha Tau Medical released positive interim results from its U.S. REGAIN trial, which is testing a treatment in patients with recurrent glioblastoma. The company did not disclose specific figures in the announcement.
Thursday, November 12, 2026
Alpha Tau Medical to Host Call on REGAIN Trial Interim Results
Alpha Tau Medical will hold a conference call to go over interim results from its REGAIN trial. The call gives the company a chance to walk through where the study stands so far.
Wednesday, November 11, 2026
Piper Sandler lifts Alpha Tau Medical rating to Overweight
Piper Sandler raised its rating on Alpha Tau Medical, moving the stock to Overweight. The prior rating was Neutral.
Piper Sandler raises Alpha Tau Medical to Overweight, price target to $22
Piper Sandler upgraded Alpha Tau Medical to Overweight and lifted its price target to $22. The change reflects the firm's updated rating and target for the stock.
Friday, October 30, 2026
Alpha Tau Medical added to Tel Aviv Stock Exchange indices
Alpha Tau Medical said it will be included in indices on the Tel Aviv Stock Exchange. Index membership can broaden a stock's visibility among local investors.
Thursday, October 29, 2026
Alpha Tau Medical added to two Tel Aviv Stock Exchange indices on November 5, 2026
Alpha Tau Medical is being included in a pair of benchmarks run by the Tel Aviv bourse, effective November 5, 2026. Membership in these gauges can widen a stock's visibility among funds that track them.
Thursday, October 22, 2026
Alpha Tau Medical, Samsung Medical Center agree to pancreatic cancer trial
The two organizations reached a memorandum of understanding tied to a clinical study in pancreatic cancer. The pact covers their joint work on that trial.
Alpha Tau Medical, Samsung Medical Center sign MoU on pancreatic cancer trial
Alpha Tau Medical and a Seoul-based hospital have agreed to explore a clinical study. The memorandum covers testing in people who have pancreatic cancer.
Tuesday, October 20, 2026
HC Wainwright Keeps $16 Target, Buy Rating on Alpha Tau Medical
HC Wainwright & Co. left its positive stance on Alpha Tau Medical unchanged, holding a $16 price target. The firm continues to rate the shares a Buy.
Monday, October 19, 2026
Alpha Tau Medical gets FDA clearance to broaden REGAIN trial
Alpha Tau Medical said the FDA approved expanding its REGAIN clinical trial. The decision lets the company enroll more patients in the study.
FDA clears Alpha Tau Medical IDE supplement for larger U.S. REGAIN trial
Alpha Tau Medical won FDA clearance for a supplement to its investigational device exemption. This lets the company grow the size of its REGAIN study in the United States.
Thursday, September 3, 2026
Barclays keeps Overweight rating on Alpha Tau Medical, lifts target to $30
Barclays reiterated an Overweight rating on Alpha Tau Medical and increased its price target to $30. The change reflects the firm's updated view on the stock.
Monday, August 31, 2026
Alpha Tau Medical completes 48-patient enrollment in IMPACT pancreatic cancer study
Alpha Tau Medical has finished signing up 48 participants for its Phase Pilot IMPACT trial, which pairs Alpha DaRT with standard chemo for pancreatic tumors that cannot be surgically removed. Early results are targeted for the start of 2027.
Tuesday, August 25, 2026
Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.
Frequently asked questions
What is the latest news on DRTS?
Nov 16, 2026: Alpha Dart Therapy clears tumors in five brain cancer patients (Benzinga) · Nov 16, 2026: Alpha Tau says Alpha DaRT worked in all eight brain cancer patients treated (Benzinga) · Nov 15, 2026: Alpha Tau Medical reports positive interim data from U.S. REGAIN trial in recurrent glioblastoma (Fiscal.ai)
What has DRTS filed with the SEC recently?
Aug 25, 2026: Alpha Tau Medical Ltd. filed an insider trading report (Form 4)
Get DRTS news as it happens
Every headline, SEC filing and analyst action for DRTS on your live chart, with important news marked and alerts when it matters.
Try SEPT Free